Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Relapsed/Refractory Pediatric B-Cell NHL/L3ALL
NCT00180895Phase 2Terminated
- Sponsor
- Gustave Roussy
- Start
- Jun 2004
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in Burkitt lymphoma (BL), Burkitt leukemia, diffuse large B-cell lymphoma (DLBCL), B-cell non-Hodgkin lymphoma, sponsored by Gustave Roussy. Started Jun 2004; status: terminated.
02
Drugs
rituximab
03
Conditions
Burkitt lymphoma (BL)Burkitt leukemiadiffuse large B-cell lymphoma (DLBCL)B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT00180895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00180895.